Clinical trial readout dates for Tarsus Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 2 lotilaner Ocular Rosacea · NCT07443202 | December 2026 Enrolling |
| Phase 2 TP-05 (lotilaner) Low Dose Lyme Disease · NCT07562087 | October 2027 Ongoing |
| Phase 2 TP-06 Persistent Corneal Epithelial Defect · NCT07886268 | July 2028 Recruiting |
Tarsus Pharmaceuticals Inc. reported $310M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $668M; at that rate the cash would last about 0 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |